Pharos iBio Co., Ltd. engages in drug development for rare and refractory diseases. It uses a drug development platform based on big data and artificial intelligence (AI) technology. The company was founded by Jung-Hyuk Yoon on April 19, 2016 and is headquartered in Anyang-si, South Korea.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company